Alimentos y salud

Medicine & Life Sciences

1. 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 11%
2. Amebiasis 7%
3. Anthracyclines 8%
4. Biomarkers 22%
5. Brain Neoplasms 6%
6. BRCA1 Gene 7%
7. BRCA2 Gene 9%
8. Breast Neoplasms 76%
9. Capecitabine 7%
10. Carcinoma in Situ 6%
11. Carica 8%
12. Caricaceae 5%
13. Carnitine 15%
14. Carnitine O-Palmitoyltransferase 7%
15. Circulating Tumor DNA 8%
16. Clinical Trials 9%
17. Colombia 7%
18. Cytomegalovirus Infections 6%
19. Dexamethasone 10%
20. Disease-Free Survival 7%
21. DNA 7%
22. Docetaxel 6%
23. Drug Therapy 20%
24. Dystrophin 6%
25. Encephalitis 5%
26. Eosine Yellowish-(YS) 8%
27. ErbB Receptors 6%
28. Estrogen Receptors 7%
29. Exons 6%
30. Fluorescein 5%
31. Fruit 5%
32. Gastritis 7%
33. Gene Expression 8%
34. Genes 11%
35. Genotype 7%
36. Glioblastoma 28%
37. Head and Neck Neoplasms 5%
38. Helicobacter Infections 11%
39. Helicobacter pylori 21%
40. Hematoxylin 9%
41. Hispanic Americans 10%
42. Human Herpesvirus 4 5%
43. Hydroxymethylglutaryl-CoA Synthase 38%
44. Immunohistochemistry 7%
45. Intestines 27%
46. Ketone Bodies 6%
47. Latin America 10%
48. Letrozole 7%
49. Liver 17%
50. Melanoma 6%
51. Messenger RNA 14%
52. Methylation 10%
53. Methyltransferases 6%
54. Mexico 5%
55. MicroRNAs 9%
56. Multiplex Polymerase Chain Reaction 7%
57. Mutation 13%
58. Neoadjuvant Therapy 7%
59. Neoplasms 27%
60. Neoplastic Stem Cells 5%
61. Oils 5%
62. Ovarian Neoplasms 10%
63. Papillomavirus Infections 6%
64. Paraffin 8%
65. Pathologists 9%
66. Peru 32%
67. Polymerase Chain Reaction 10%
68. Population 7%
69. Proteomics 5%
70. Pyruvic Acid 5%
71. Radiotherapy 7%
72. Regulator Genes 17%
73. Residual Neoplasm 6%
74. Restriction Fragment Length Polymorphisms 5%
75. Risk Management 12%
76. Seeds 5%
77. Small Intestine 5%
78. Staining and Labeling 9%
79. Stomach Neoplasms 21%
80. Survival 17%
81. Therapeutics 8%
82. Transferases 13%
83. Triple Negative Breast Neoplasms 42%
84. Tuberculosis 9%
85. Tumor-Infiltrating Lymphocytes 100%
86. Weaning 5%